Semaglutide cuts obesity, improves Heart Failure symptoms in Atrial Fibrillation: JACC

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-10-22 03:30 GMT | Update On 2024-10-22 07:31 GMT

A recent secondary analysis from the pooled data of the STEP-HFpEF (Heart Failure with Preserved Ejection Fraction) Program and STEP-HFpEF DM found that once a week's prescription of Semaglutide 2.4 mg has led to significant improvements in Heart failure-related symptoms and physical limitations in individuals with Atrial Fibrillation (AF) at the baseline than those without AF.

Results from this analysis were published in the Journal of American College of Cardiology.

AF is frequently observed in individuals with HFpEF and leads to adverse outcomes in these individuals compared to those with normal sinus rhythm. Obesity is an important risk factor for the development and progression of HFpEF and AF. Previous research from the HFpEF and HFpEF DM trials showed that Semaglutide had better results in those with HF-related symptoms, physical limitations, exercise function, body weight, and obesity-related heart failure in obesity-related HFpEF. However, there is uncertainty on the efficacy of semaglutide in individuals with or without AF. Hence, researchers conducted a secondary analysis from the pooled data of the two trials to evaluate the baseline characteristics, and clinical features, of obesity-related HFpEF individuals with and without a history of AF. They also determined the efficacy of Semaglutide across various types of AF.

Individuals with heart failure, left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m2, and Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score (KCCQ-CSS) <90 points were randomized 1:1 to receive once-weekly semaglutide 2.4 mg or matching placebo for 52 weeks. The endpoints investigated based on the investigator-reported history of AF included the following:

• Primary - change in KCCQ-CSS and percent change in body weight Confirmatory

• Secondary - change in 6-minute walk distance, all-cause death, HF events, thresholds of change in KCCQ-CSS, and 6-minute walk distance; and C-reactive protein

• Exploratory endpoint - change in N-terminal pro–B-type natriuretic peptide

Based on the presence of AF, the responder analysis examined the improvements in the KCCQ-CSS score

Findings:

• Among 1145 individuals, 45% had a history of AF of different types Most of them with AF were older, male, with high levels of NTproBNP, were among the NYHA functional class III symptoms, and were taking more antithrombotics, beta-blockers, and diuretics.

• A significant improvement in the KCCQ-CSS score (11.5 vs 4.3 points was seen in the individuals with AF vs without AF A significant proportion of individuals with AF taking semaglutide reported ≥5-, ≥10-, ≥15-, and ≥20-point improvement in KCCQ-CSS than without AF and on placebo.

• Apart from these a consistent reduction in the CRP, NT-proBNP, and body weight was seen despite the AF status with semaglutide.

Thus, the study concluded that semaglutide was effective in improving HF-related symptoms and obesity-related heart failure with pronounced improvements in individuals with AF. Semaglutide proves to be a potential drug for improving heart failure symptoms and obesity in individuals with AF.

Further reading: Verma S, Butler J, Borlaug BA, et al. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024;84(17):1603-1614. doi:10.1016/j.jacc.2024.08.023.

Article Source : Journal of American College of Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr.Niharika Harsha B

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Semaglutide cuts obesity, improves Heart Failure symptoms in Atrial Fibrillation: JACC

Similar News

CTI Linked to Higher Mortality in People with Both Heart Disease and Type 2 Diabetes: Study

Medical Bulletin 18/Jul/2025

Stress Hyperglycemia Ratio Identified as Predictor of Early Mortality in Acute CV Disease: Study

Can Nighttime Avocado Snack Improve Heart Health? New Study Says Yes

Baxdrostat Significantly Lowers Blood Pressure in Resistant Hypertension in Phase 3 trial

Lipid Ratios Linked to Higher Gestational Diabetes Risk: Study on 6,600 Pregnant Women Reveals

GLP-1 Receptor Agonists Promising in Managing Idiopathic Intracranial Hypertension: JAMA Study

Late eating is associated with impaired glucose metabolism, suggests study